Search Within

Taha Merghoub

  1. "David Solit"
Formats
  1. Journal Article (9)
  2. Meeting Abstract (5)
Groups
  1. Department of Medicine (14)
  2. GSK Faculty (14)
  3. Genitourinary Oncology Service (14)
  4. Human Oncology and Pathogenesis Program (14)
  5. Melanoma and Immunotherapeutics Service (14)
  6. Solid Tumor Oncology Division (14)

More Groups

People
  1. David Solit (14)
  2. Michael Berger (7)
  3. Neal Rosen (6)
  4. Paul Chapman (6)
  5. James Harding (5)
  6. Nikolaus Schultz (5)

More People

Years
  1. 2023 (2)
  2. 2022 (1)
  3. 2021 (1)
  4. 2020 (2)
  5. 2018 (1)
  6. 2017 (1)

More Years

Publications
  1. Journal of Clinical Oncology (6)
  2. Cancer Research (2)
  3. Cancer Discovery (1)
  4. Clinical Cancer Research (1)
  5. JCO Precision Oncology (1)
  6. New England Journal of Medicine (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (7)
  2. American Association for Cancer Research (4)
  3. Massachusetts Medical Society (1)
  4. Nature Publishing Group (1)
  5. Oxford University Press (1)

Results (14)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Determinants of survival with combined HER2 and PD-1 blockade in metastatic esophagogastric cancer
    Journal Article

    Maron, S. B.; Chatila, W.; Walch, H.; Chou, J. F.; Ceglia, N.; Ptashkin, R.; Do, R. K. G.; Paroder, V.; Pandit-Taskar, N.; Lewis, J. S.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Characterizing the immune phenotype of FGFR3 mutated upper tract urothelial carcinoma (UTUC) using single-cell (sc)RNA-sequencing (seq)
    Meeting Abstract

    Katims, A. B.; Kuo, F.; Reisz, P.; Tracey, A.; Thomas, J.; Yip, W.; Merghoub, T.; Bochner, B. H.; Pietzak, E. J.; Solit, D. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Upper tract urothelial carcinoma transcriptome profiling and immune microenvironment characterization
    Meeting Abstract

    Yip, W.; Kim, K.; Kuo, F.; Lenis, A. T.; Chen, J. F.; Hu, W.; Clinton, T. N.; Chu, C. E.; Almassi, N.; Tracey, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Walch, H. S.; Ptashkin, R.; Sabwa, S.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Millang, B. M.; Sabwa, S.; Chou, J. F.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Leveraging systematic functional analysis to benchmark an in silico framework distinguishes driver from passenger MEK mutants in cancer
    Journal Article

    Hanrahan, A. J.; Sylvester, B. E.; Chang, M. T.; Elzein, A.; Gao, J.; Han, W.; Liu, Y.; Xu, D.; Gao, S. P.; Gorelick, A. N.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing
    Journal Article

    Rizvi, H.; Sanchez-Vega, F.; La, K.; Chatila, W.; Jonsson, P.; Halpenny, D.; Plodkowski, A.; Long, N.; Sauter, J. L.; Rekhtman, N.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • PTEN loss-of-function alterations are associated with intrinsic resistance to BRAF inhibitors in metastatic melanoma
    Journal Article

    Catalanotti, F.; Cheng, D. T.; Shoushtari, A. N.; Johnson, D. B.; Panageas, K. S.; Momtaz, P.; Higham, C.; Won, H. H.; Harding, J. J.; Merghoub, T.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases
    Journal Article

    Harding, J. J.; Catalanotti, F.; Munhoz, R. R.; Cheng, D. T.; Yaqubie, A.; Kelly, N.; McDermott, G. C.; Kersellius, R.; Merghoub, T.; Lacouture, M. E.; more...
    The Oncologist (2015)

    Fulltext@MSK | Save
  • Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence
    Journal Article

    Nissan, M. H.; Pratilas, C. A.; Jones, A. M.; Ramirez, R.; Won, H.; Liu, C.; Tiwari, S.; Kong, L.; Hanrahan, A. J.; Yao, Z.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save